|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: South Africa
Espicom Business Intelligence Ltd, Sep 2009, Pages: 56
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
South Africa has one of the highest rates of HIV/AIDS infections in the world; according to latest government estimates, around 5.4 million people were infected by HIV, just over 10% of the entire population. The true picture could be even more widespread, as these estimates were derived using mathematical models based on surveys done on pregnant women.
The market for antiretroviral (ARV) drugs looks set to grow; after years of not addressing the severity of the problem, the government has now started to look at ways to increase the supply of these drugs via the public system.
In June 2009, president Jacob Zuma, in his first State to the Nation Address endorsed the establishment of a National Health Insurance (NHI) scheme. Zuma said the scheme, which aims to provide universal health for all South Africans, will be implemented in phases. There is little detailed information, at this stage, on how the scheme is to be implemented.
International tendering exists, but as Aurobindo, one of the world’s largest producers of generic ARV drugs found out, does not always work in favour international companies. The Indian drugmaker, in June 2009, announced that it plans to sue the government, on claims that it had lost out to local manufacturers in a R400 million (US$38.1 million) contract for ARVs, although its price was 30% cheaper on the tender.
The government increased prices by 5% in 2006, and 6% across 2007 and 2008, but the industry complained these increases were below the rate of inflation. In January 2009, prices were increased by 13.2% by the DOH, a move that was welcomed by the Pharmaceutical Industry Association of South Africa (PIASA), which said the increase helped combat increasing margin pressures experienced in 2008 due to mainly imported raw materials against a weakening local currency.
The government, although wanting to back the local industry with protectionist measures, could be tempted to procure more drugs from countries like India and China, who can provide a higher volume of drugs for the same tender price compared to local companies.
Customers who bought this item also bought
The Pharmaceutical Market: South Korea
Pharmaceutical Industry in South Africa
The Medical Device Market: South Korea
The Pharmaceutical Market: Bulgaria
The Pharmaceutical Market: Greece
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Romania
The Pharmaceutical Market: New Zealand
Executive Report on Strategies in South Africa
The Pharmaceutical Market: Belgium
Biopharmaceuticals in South East Asia
The Pharmaceutical Market: Morocco
|
|
|
|
